Haemonetics (HAE) Tops Q2 EPS by 16c; offers guidance
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $109.54 +1.80%
EPS Growth %: 0.0%
Financial Fact:
Net income: 0.38
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: 0.0%
Financial Fact:
Net income: 0.38
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q2 EPS of $1.27, $0.16 better than the analyst estimate of $1.11. Revenue for the quarter came in at $327 million versus the consensus estimate of $311.46 million.
GUIDANCE:
Haemonetics sees FY2026 EPS of $4.80-$5.00, versus the consensus of $4.83.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Freedom Broker Downgrades Nucor (NUE) to Hold, 'Guides Conservative Earnings Yet Again'
- EMA panel backs Novartis Cosentyx for rheumatic condition in EU
- Pinduoduo (PDD) call put ratio 5.4 calls to 1 put into President Donald Trump and Chinese President Xi Jinping's summit
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
